In this large study of children and adolescents based on data from routine clinical practice, there was no association between use of montelukast and the risk of neuropsychiatric adverse events. In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group.
Intranasal steroids are the most effective pharmacologic treatment for seasonal allergic rhinitis (SAR), but they can take several days to take effect, and some patients don't achieve full relief of symptoms. Add-on oral antihistamines or montelukast (Singulair) do not add much benefit.
Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years. When symptomatic, patients report significant reduction in their quality of life and impairment in school and work performance. Achieving adequate symptom control is pivotal to successful allergic rhinitis management, and relies mostly on pharmacotherapy. Whil…
A previous meta-analysis suggested that the treatment with erdosteine was associated with significant amelioration of the cumulative global efficacy index and symptoms in comparison to placebo or other mucolytics. However, this conclusion was criticized because the meta-analysis, as it had been done, made it impossible to preclude the potential operation of selection biases within and across t…
Guideline-based management of asthma focuses on disease severity and choosing the appropriate medical therapy to control symptoms and reduce the risk of exacerbations. However, irrespective of asthma severity and often despite optimal medical therapy, patients may experience acute exacerbations of symptoms and a loss of disease control. Asthma exacerbations are most commonly triggered by vir…
Allergic rhinitis (AR) and asthma represent global healthproblems for all age groups. Asthma and rhinitis frequentlycoexist in the same subjects. Allergic Rhinitis and its Impact onAsthma (ARIA) was initiated during a World HealthOrganizationworkshop in 1999 (published in 2001). ARIA has reclassified AR asmild/moderate-severe and intermittent/persistent
Asthma is a common chronic inflammatory disease of the airways characterized by airway obstruction and hyperresponsiveness. Leukotrienes (LTs) are lipid mediators that contribute to many aspects of asthma pathogenesis. As the LT pathway is relatively steroid-resistant, its blockade by alternative strategies is a desirable component of asthma management. Cysteinyl LT receptor 1 antagonists have …
Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting b2-agonists (LABA) or both, necessitating additional treatment. Patients 18 years (n Z 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS þ LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint …
Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects
Cough variant asthma (CVA) is a phenotype of asthma presenting solely with coughing, characterized by airway hyperresponsiveness, eosinophilic inflammation and a cough response to bronchodilators. Leukotriene receptor antagonists (LTRAs) are antiasthma medications with antiinflammatory and bronchodilatory properties. Although LTRAs exert antitussive effects in CVA, the mechanisms involved are u…